Universal reference book for medicines
Name of the drug: UROPROST (UROPROST)

Active substance: nonappropriate

Type: Animal preparation used for prostate diseases

Manufacturer: АЛЬТФАРМ (Russia)
Composition, form of production and packaging
?
Suppositories rectal 1 supp.
extract of bovine prostate 50 mg

5 pieces.
- packings cellular planimetric (2) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2013.

PHARMACHOLOGIC EFFECT

The drug has anti-inflammatory and antiaggregatory action, stimulates the muscles of the bladder.

The active substances of the extract of the prostate are referred to the group of peptide bioregulators - cytomedines.
These drugs are basic peptides with a molecular weight of 1 to 10 kDa. Low-molecular peptides of a para- or autocrine nature, perform the function of trans-specific intra- and intercellular messengers.
Prostatic gland peptides reduce clotting time and increase antiaggregatory activity of the vascular wall, improve blood microcirculation, increase fibrinolytic activity of blood activity, increase the contractile activity of detrusor myocytes in vivo, in vitro.
Have immunomodulatory and immunostimulating effect, enhance the synthesis of antihistamines and antiserotonin antibodies.
The use of peptide bioregulators in the treatment of chronic prostatitis is the ability of these drugs to restore microcirculation, to have an indirect anti-inflammatory effect by enhancing the synthesis of antihistamine and antiserotonin antibodies, as well as their immunomodulating and immunostimulating effects.

Treatment of benign prostatic hyperplasia is based on the most important biological effect of cytomedins: organotropic, allowing.
regulate the processes of differentiation and function of cells in the organ from which they are isolated.
PHARMACOKINETICS

As a peptide drug, it is cleaved by cellular proteases up to amino acids.
No cumulative effect.
INDICATIONS

- chronic prostatitis;

- condition before and after operations on the prostate gland;

benign prostatic hyperplasia.

DOSING MODE

The drug is used rectally.
After releasing the suppository from the contoured package, it is injected into the anus after defecation or cleansing enema.
Apply 1 suppository 1 time per day.

After the administration of the drug, it is desirable to stay in bed for 30-40 min.
Duration of treatment - 20 days.
According to the testimony, repeated courses are possible;
it is recommended to hold no earlier than 2-4 weeks.
SIDE EFFECT

The peculiarities of the technology of isolation of these peptides level their molecular species-specificity, as a result of which the obtained preparations are deprived of antigenic properties and associated side effects.

Often - 1-10%;
sometimes 0.1-1%; rarely - 0,01-0,1%; very rarely - less than 0.01%, including individual cases.
Very rarely - allergic reactions, often - itching in the anus, sometimes diarrhea, flatulence.

CONTRAINDICATIONS

- Individual intolerance (including hypersensitivity in anamnesis).

PREGNANCY AND LACTATION

Not applicable to women.

SPECIAL INSTRUCTIONS

Treatment of chronic prostatitis should be complex, involving the use of different groups of drugs and non-drug therapies.
In the treatment it is recommended to perform an analysis of the secretion of the prostate gland
OVERDOSE

Currently, there have been no cases of overdose.

DRUG INTERACTION

Negative interaction was not observed.
The drug can be used for complex therapy.
TERMS OF RELEASE FROM PHARMACY

Without recipe.

TERMS AND CONDITIONS OF STORAGE

In the dark place at a temperature of no higher than 25 В° C.
Keep away from children. Shelf life - 2 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y

Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!